Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.

ABSTRACT:

Background

Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has shown promising results in clinical trials and real-world studies.

Methods

PubMed/MEDLINE, Web of Science, EMBASE, Cochrane Library, ClinicalTrials.gov, and meeting libraries were searched from inception to 14 November 2024. The assessed outcomes included overall survival (OS), progression-free survival, time to next treatment, duration of response, overall response rate (ORR), ≥complete response (≥CR), ≥very good partial response (≥VGPR), VGPR, partial response, and adverse events.

Results

In total, 34 studies involving 4,064 patients were included.

SUBMITTER: Li W 

PROVIDER: S-EPMC12061972 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature